Semaglutide

semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogue developed by NovoNordisk, a Danish company. Semaglutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in the treatment of type 2 diabetes. Novo Nordisk has completed six PChemicalbookhaseIIIa studies for its Somarutide injection and submitted an application to the U.S. Food and Drug Administration (FDA) on December 5, 2016 for New Drug registration for its once-a-week Somarutide injection. An application for Marketing Authorization (MAA) has also been submitted to the European Medicines Agency (EMA). A once-daily oral formulation of Sommarutide, on the other hand, is currently in phase III.